Harvard Bioscience (HBIO) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
30 Jan, 2026Executive summary
Special Meeting scheduled for March 6, 2026, to vote on a reverse stock split and potential adjournment to solicit more proxies if needed.
Reverse stock split proposed at a ratio between 1-for-5 and 1-for-15 to regain Nasdaq compliance.
Board recommends voting in favor of both proposals to maintain Nasdaq listing and flexibility.
If approved, the Board may implement the split within six months or abandon it if not in the best interest of shareholders.
Proxy materials and voting instructions provided for online, phone, and mail participation.
Voting matters and shareholder proposals
Proposal 1: Approve amendment for reverse stock split at a ratio of 1-for-5 to 1-for-15.
Proposal 2: Authorize adjournment of the meeting to solicit additional proxies if Proposal 1 lacks sufficient votes.
Majority of votes cast required for approval; broker non-votes and abstentions have no impact.
Board recommends voting "FOR" both proposals.
Stockholder proposals for the 2026 annual meeting must comply with SEC and bylaw deadlines.
Board of directors and corporate governance
Board retains discretion to implement or abandon the reverse stock split within six months of approval.
No current arrangements for additional share issuance post-split.
Board believes higher share price may attract institutional investors and facilitate financing.
Latest events from Harvard Bioscience
- Gross margin rose to 59% as revenue fell, with stable EBITDA and cost-saving initiatives underway.HBIO
Q1 202612 May 2026 - Strategic focus, operational streamlining, and innovation drive growth and recurring revenue.HBIO
Investor presentation12 May 2026 - Both proposals, including a reverse stock split, passed with over 97% approval.HBIO
EGM 20267 May 2026 - Margins improved and 2026 guidance targets growth from new products and operational discipline.HBIO
Q4 202528 Apr 2026 - Key votes include director elections, auditor ratification, and equity plan share increases.HBIO
Proxy filing22 Apr 2026 - Shareholders will vote on director elections, auditor ratification, executive pay, and equity plan amendments.HBIO
Proxy filing22 Apr 2026 - Strategic focus, innovation, and operational efficiency drive margin and recurring revenue growth.HBIO
2026 KeyBanc Capital Markets Healthcare Forum20 Mar 2026 - Q2 2024 revenue fell nearly 20% with net loss widening, prompting reduced full-year guidance.HBIO
Q2 20242 Feb 2026 - Growth driven by new organoid and bioproduction systems, with APAC recovery boosting outlook.HBIO
Jefferies Global Healthcare Conference1 Feb 2026